Cholangiocarcinoma in PSC after long-time treatment with ursodeoxycholic acid.

[Guest guest]

Eur J Gastroenterol

Hepatol. 2007 Jun ;19 (6):487-91 17489059

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after

long-time treatment with ursodeoxycholic acid. [My

paper]

Gerda

Rudolph , Petra Kloeters-Plachky

, Rost

, Adolf

Stiehl

BACKGROUND/AIMS: Cholangiocarcinoma represents a

serious complication of primary sclerosing cholangitis. Ursodeoxycholic

acid may possibly influence the incidence of cholangiocarcinoma in man. The aim of this study was to evaluate the incidence rate

of cholangiocarcinoma in a large group of primary sclerosing

cholangitis patients after long-time treatment with ursodeoxycholic acid. PATIENTS AND

METHODS: From May 1987 up to May 2005 a total of 150 patients with primary sclerosing cholangitis but

without evidence of cholangiocarcinoma at entry were included in the study. All patients were treated with ursodeoxycholic

acid and controls were performed in at least yearly intervals.

RESULTS: The median treatment time of the 150 patients was 6.4 years. Altogether five patients developed a cholangiocarcinoma

during treatment yielding a rate of 3.3%. The patients

developed 0.58 cholangiocarcinoma per 100 patient-years in years 0-2.5, 0.59

cholangiocarcinoma in years 2.5-8.5, and no cholangiocarcinoma thereafter up to

18 years after entry into the study. The Kaplan-Meier

estimate of cholangiocarcinoma incidence during ursodeoxycholic

acid treatment reached a plateau after 8.3 years.

SUMMARY AND CONCLUSION: The annual incidence

rate of cholangiocarcinoma in primary sclerosing cholangitis treated with ursodeoxycholic

acid is lower than expected and decreases with time of treatment.

Barb in Texas - Together in the Fight, Whatever it Takes!

Son Ken (33) UC 91 - PSC 99 - Tx 6/21 & 6/30/07 @ Baylor in Dallas

[Guest guest]

Barb,

I like the conclusion of this one.

Regards,

Chaim Boermeester, Israel

From:

[mailto: ] On Behalf Of Barb Henshaw

Sent: Friday, November 30, 2007

00:56

To:

Subject:

Cholangiocarcinoma in PSC after long-time treatment with ursodeoxycholic acid.

Eur J Gastroenterol

Hepatol. 2007 Jun ;19 (6):487-91 17489059

The

incidence of cholangiocarcinoma in primary sclerosing

cholangitis after long-time treatment with ursodeoxycholic acid. [My paper]

Gerda Rudolph , Petra Kloeters-Plachky

, Rost

, Adolf Stiehl

BACKGROUND/AIMS: Cholangiocarcinoma represents a serious

complication of primary sclerosing cholangitis. Ursodeoxycholic

acid may possibly influence the incidence of cholangiocarcinoma in man. The aim of this study was to evaluate the incidence rate

of cholangiocarcinoma in a large group of primary sclerosing

cholangitis patients after long-time treatment with ursodeoxycholic acid. PATIENTS AND

METHODS: From May 1987 up to May 2005

a total of 150 patients with primary sclerosing

cholangitis but without evidence of

cholangiocarcinoma at entry were included in the study. All

patients were treated with ursodeoxycholic acid and controls

were performed in at least yearly intervals. RESULTS:

The median treatment time of the 150 patients was 6.4 years. Altogether

five patients developed a cholangiocarcinoma during treatment yielding a rate

of 3.3%. The patients developed 0.58 cholangiocarcinoma

per 100 patient-years in years 0-2.5, 0.59 cholangiocarcinoma in years 2.5-8.5,

and no cholangiocarcinoma thereafter up to 18 years after entry into the study. The Kaplan-Meier estimate of cholangiocarcinoma incidence

during ursodeoxycholic acid treatment reached a

plateau after 8.3 years.

SUMMARY AND CONCLUSION: The annual incidence rate

of cholangiocarcinoma in primary sclerosing cholangitis treated with ursodeoxycholic

acid is lower than expected and decreases with time of treatment.

Barb in Texas

- Together in the Fight, Whatever it Takes!

Son Ken (33) UC 91 - PSC 99

- Tx 6/21 & 6/30/07 @ Baylor in Dallas